SNAP-CAR T

SNAP-CAR T is a novel, universal chimeric antigen receptor (CAR) T cell therapy platform developed to enhance the flexibility and control of cell-based immunotherapies. Unlike conventional CAR-T therapies that target a single tumor antigen via a fixed receptor, the SNAP-CAR system incorporates a self-labeling enzyme called "SNAPtag" into the extracellular domain of the CAR. This allows for covalent binding to benzylguanine (BG)-conjugated antibodies that are co-administered with the engineered cells. The antibody adaptors direct specificity by targeting different tumor antigens; thus, changing or combining BG-conjugated antibodies enables programmable and multi-antigen targeting in real time. The covalent bond between the antibody adaptor and the SNAPtag on the engineered T cell is highly stable and tunable—antibody dose can be adjusted to modulate potency or reduce toxicity such as cytokine release syndrome. This modular approach allows for rapid retargeting against evolving tumors or multiple antigens simultaneously, potentially reducing relapse due to antigen loss. Preclinical studies have demonstrated potent anti-tumor activity in mouse models using this technology. The platform supports both autologous and allogeneic settings and can be applied not only with T cells but also NK cells. Coeptis Therapeutics has licensed this technology from researchers at University of Pittsburgh[1][2][3][7].

Other names

SNAP CAR-TSNAPtag CAR-T